RCAG
ADAP

Rehmann Capital Advisory Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-48
Closed -$276 – 2086
2018
Q4 		$276 Hold
48
– – ﹤0.01% 1781
2018
Q3 		$650 Hold
48
– – ﹤0.01% 2046
2018
Q2 		$570 Hold
48
– – ﹤0.01% 2047
2018
Q1 		$1K Buy
+48
New +$420 ﹤0.01% 1827

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rehmann Capital Advisory Group's ADAP Position: Q1 2019 in Review

Rehmann Capital Advisory Group sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 48 shares — an estimated $276 sold.

Rehmann Capital Advisory Group first reported a position in ADAP in Q1 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Rehmann Capital Advisory Group reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 48 Adaptimmune Therapeutics shares in Q1 2019, an estimated $276.
  • Rehmann Capital Advisory Group first reported a position in Adaptimmune Therapeutics in Q1 2018 and held it in 4 quarters.
  • Rehmann Capital Advisory Group's Adaptimmune Therapeutics position peaked at $1K in Q1 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2019, filed 22 May 2019.